Advanced Oncotherapy plc (AVO.L)

1,9250 0,0000 (0,00%) Börsenschluss: 04:23PM BST

Advanced Oncotherapy plc

143 Harley street
Ground floor
London W1G 6BH
United Kingdom
44 20 3617 8728
https://www.avoplc.com

Sektor(en): Healthcare
Branche: Medical Devices
Vollzeitmitarbeiter: 174

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Michael Jeffrey Sinclair	Executive Chairman	434,42k	N/A	1942
Mr. Nicolas Serandour	CEO & Executive Director	502,96k	N/A	1975
Prof. Stephen Myers OBE	Executive Director	397,72k	N/A	1946
Mr. Ed Lee	COO & President of Europe	N/A	N/A	N/A
Mr. Graham Pughe	Senior Vice-President of Accounting	N/A	N/A	N/A
Ms. Berengere Pons-Chabord	Senior Vice-President of Corporate Finance	N/A	N/A	N/A
Mr. David Navas	Vice President of Investor and Public Relations	N/A	N/A	N/A
Ms. Bridget Biggar	Director of Human Resources	N/A	N/A	N/A
Ms. Donatella Ungaro	Managing Director of ADAM	N/A	N/A	N/A
Ms. Marina Giunta	Head of Physics Group	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in GBp.

Beschreibung

Advanced Oncotherapy plc, together with its subsidiaries, engages in designing, assembling, and selling proton-based radiotherapy systems for treatment of cancer. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. The company also engages in the management of healthcare related properties. It has operations in the United Kingdom, Switzerland, and the United States. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy PLC in September 2012. Advanced Oncotherapy plc was founded in 1994 and is headquartered in London, the United Kingdom.

Corporate Governance

Advanced Oncotherapy plcs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.